In line with this recognized paradigm, we found that virus infection activated PLC-γ1 partially through EGFR, as treatment with the EGFR specific inhibitor Gefitinib led to a significant inhibition of PLC-γ1 phosphorylation in virus-infected cells (Figure 6). This evidence concerns the gene PLCG1 and viral infectious disease.